PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring

PAVmed Inc.

Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).
Regained compliance via exchange of $22.3M notes for Series C preferred, $2.653M new preferred issuance, and Lucid Diagnostics deconsolidation.
Subject to one-year Mandatory Panel Monitor until Feb 14, 2026; new deficiency could trigger delisting.
Company previously received hearing panel extension to Jan 31, 2025 after failing market value rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.